“Current CMS payment methodology for radiopharmaceuticals averages both new innovations and older widely used drugs, resulting in taxpayers overpaying for the low-cost imaging drugs while significantly underpaying for more specialized drugs,” said Rep. Neal Dunn, MD. “The FIND Act addresses this discrepancy, ultimately improving access to imaging drugs that can efficiently and accurately diagnose conditions like Alzheimer’s and Parkinson’s disease, advanced cardiac disease, and prostate and other cancers.”

“Diagnostic nuclear imaging is a revolutionary technology that allows physicians to evaluate organ function and optimizes their ability to determine the best treatment for patients. Yet for years, flawed Medicare policy has meant Americans have not had appropriate access to diagnostic nuclear imaging procedures,” said Patrick Hope, Executive Director of the Medical Imaging and Technology Alliance. “We encourage Congress to pass the FIND Act and allow more Americans to receive early, accurate diagnoses and improve treatment outcomes.”


###

The Medical Imaging & Technology Alliance (MITA), a division of NEMA, is the collective voice of medical imaging equipment manufacturers, innovators, and product developers. It represents companies whose sales comprise more than 90 percent of the global market for advanced medical imaging technology. For more information, visit www.medicalimaging.org. Follow MITA on Twitter @MITAToday.

Back to HCB News

Molecular Imaging Homepage